CO2024001551A2 - Proteínas actrii y usos de las mismas - Google Patents
Proteínas actrii y usos de las mismasInfo
- Publication number
- CO2024001551A2 CO2024001551A2 CONC2024/0001551A CO2024001551A CO2024001551A2 CO 2024001551 A2 CO2024001551 A2 CO 2024001551A2 CO 2024001551 A CO2024001551 A CO 2024001551A CO 2024001551 A2 CO2024001551 A2 CO 2024001551A2
- Authority
- CO
- Colombia
- Prior art keywords
- telangiectasia
- risk
- effective amount
- therapeutically effective
- patient receiving
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 206010043189 Telangiectasia Diseases 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 208000009056 telangiectasis Diseases 0.000 abstract 2
- 230000007423 decrease Effects 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163223265P | 2021-07-19 | 2021-07-19 | |
| PCT/US2022/037479 WO2023003815A1 (en) | 2021-07-19 | 2022-07-18 | Actrii proteins and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2024001551A2 true CO2024001551A2 (es) | 2024-03-07 |
Family
ID=84979535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2024/0001551A CO2024001551A2 (es) | 2021-07-19 | 2024-02-14 | Proteínas actrii y usos de las mismas |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20240327494A1 (https=) |
| EP (1) | EP4373577A4 (https=) |
| JP (1) | JP2024526820A (https=) |
| KR (1) | KR20240049857A (https=) |
| CN (1) | CN117957014A (https=) |
| AU (1) | AU2022316103A1 (https=) |
| CA (1) | CA3225613A1 (https=) |
| CL (1) | CL2024000151A1 (https=) |
| CO (1) | CO2024001551A2 (https=) |
| CR (1) | CR20240061A (https=) |
| DO (1) | DOP2024000016A (https=) |
| EC (1) | ECSP24012819A (https=) |
| GE (1) | GEAP202416461A (https=) |
| IL (1) | IL310141A (https=) |
| JO (1) | JOP20240010A1 (https=) |
| MX (1) | MX2024000829A (https=) |
| PE (1) | PE20240777A1 (https=) |
| WO (1) | WO2023003815A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021189010A1 (en) | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| WO2021189019A1 (en) | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Activin receptor type ii chimeras and methods of use thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180055822A1 (en) * | 2015-03-13 | 2018-03-01 | Repoceuticals Aps | Melatonin for Preventing and Treating Radiation Cystitis |
| EP3380121B1 (en) * | 2015-11-23 | 2023-12-20 | Acceleron Pharma Inc. | Actrii antagonist for use in treating eye disorders |
| DK3496739T3 (da) * | 2016-07-15 | 2021-05-10 | Acceleron Pharma Inc | Sammensætninger omfattende actriia-polypeptider til brug i behandlingen af pulmonal hypertension |
-
2022
- 2022-07-18 PE PE2024000111A patent/PE20240777A1/es unknown
- 2022-07-18 EP EP22846466.5A patent/EP4373577A4/en active Pending
- 2022-07-18 CR CR20240061A patent/CR20240061A/es unknown
- 2022-07-18 US US18/580,425 patent/US20240327494A1/en active Pending
- 2022-07-18 JP JP2024502611A patent/JP2024526820A/ja active Pending
- 2022-07-18 CA CA3225613A patent/CA3225613A1/en active Pending
- 2022-07-18 WO PCT/US2022/037479 patent/WO2023003815A1/en not_active Ceased
- 2022-07-18 MX MX2024000829A patent/MX2024000829A/es unknown
- 2022-07-18 IL IL310141A patent/IL310141A/en unknown
- 2022-07-18 GE GEAP202416461A patent/GEAP202416461A/en unknown
- 2022-07-18 KR KR1020247005282A patent/KR20240049857A/ko active Pending
- 2022-07-18 AU AU2022316103A patent/AU2022316103A1/en active Pending
- 2022-07-18 CN CN202280060109.7A patent/CN117957014A/zh active Pending
-
2024
- 2024-01-17 CL CL2024000151A patent/CL2024000151A1/es unknown
- 2024-01-18 DO DO2024000016A patent/DOP2024000016A/es unknown
- 2024-01-18 JO JOJO/P/2024/0010A patent/JOP20240010A1/ar unknown
- 2024-02-14 CO CONC2024/0001551A patent/CO2024001551A2/es unknown
- 2024-02-19 EC ECSENADI202412819A patent/ECSP24012819A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023003815A1 (en) | 2023-01-26 |
| JOP20240010A1 (ar) | 2024-01-18 |
| CR20240061A (es) | 2024-05-02 |
| US20240327494A1 (en) | 2024-10-03 |
| ECSP24012819A (es) | 2024-03-01 |
| CN117957014A (zh) | 2024-04-30 |
| MX2024000829A (es) | 2024-04-12 |
| GEAP202416461A (en) | 2024-04-25 |
| CA3225613A1 (en) | 2023-01-26 |
| EP4373577A4 (en) | 2025-05-14 |
| AU2022316103A1 (en) | 2024-02-08 |
| EP4373577A1 (en) | 2024-05-29 |
| JP2024526820A (ja) | 2024-07-19 |
| KR20240049857A (ko) | 2024-04-17 |
| PE20240777A1 (es) | 2024-04-17 |
| WO2023003815A9 (en) | 2023-05-11 |
| CL2024000151A1 (es) | 2024-08-09 |
| IL310141A (en) | 2024-03-01 |
| DOP2024000016A (es) | 2024-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1126062T1 (el) | Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1 | |
| CO2024001551A2 (es) | Proteínas actrii y usos de las mismas | |
| MX2022015272A (es) | Inhibidores de la proteina kras g12c y usos de estos. | |
| AR107303A1 (es) | Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit | |
| CL2019002190A1 (es) | Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984) | |
| MX2022010774A (es) | Composiciones que comprenden aminoacidos para su uso en el tratamiento de enfermedades relacionadas con la disfuncion mitocondrial. | |
| CR20210373A (es) | Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp | |
| MX2021008268A (es) | Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r. | |
| MX2020007760A (es) | Composiciones y metodos para mejorar la biodisponibilidad de 5-hidroxitriptofano. | |
| CO2022005889A2 (es) | Derivados terapéuticos de interleucina-22 | |
| CL2021001044A1 (es) | Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrización de heridas y la recuperación posoperatoria | |
| CL2019001749A1 (es) | Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta. | |
| CO2021015793A2 (es) | Métodos para tratar o prevenir el asma mediante la administración un antagonista de il-33 | |
| CL2019002218A1 (es) | Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular. | |
| CO2021014260A2 (es) | Formas sólidas de un inhibidor de glyt1 | |
| CL2022001035A1 (es) | Composiciones y métodos para minimizar la pérdida de proteínas a concentraciones de proteínas bajas | |
| PE20190171A1 (es) | Anticuerpos de union a trombina y usos del mismo | |
| MX2021003263A (es) | Combinacion de un antagonista de proteina de muerte programada 1 (pd-1), un inhibidor de ataxia telangiectasia y proteina relacionada con rad3 (atr) y un agente de platino para el tratamiento de cancer. | |
| AR104721A1 (es) | Fragmento fab anti-ngf humano | |
| AR115883A1 (es) | Composición farmacéutica para el tratamiento de la adicción a sustancias psicoactivas y/o para la prevención de las recaídas a dicha adicción | |
| DOP2025000170A (es) | Proteínas de fusión fc de il-12 | |
| EA201891752A2 (ru) | Фармацевтическая композиция для улучшения состояния при хронической почечной недостаточности или предотвращения ее прогрессирования | |
| CL2021002866A1 (es) | Tratamiento de la cefalea usando anticuerpos anti-cgrp. | |
| BR112022004809A2 (pt) | Compostos 2-amino-s6-tiopurina substituídos como inibidores da proteína enpp1 | |
| EA202190504A1 (ru) | Способы лечения псориаза |